(Q31871277)

4 July 2017

1 reference

title

The treatment of undifferentiated neuroendocrine tumors (English)

1 reference

4 July 2017

Mitry E

1

1 reference

4 July 2017

Rougier P

series ordinal

2

1 reference

4 July 2017

publication date

1 January 2001

1 reference

Critical Reviews in Oncology Hematology

4 July 2017

published in

1 reference

4 July 2017

volume

37

1 reference

4 July 2017

issue

1

1 reference

4 July 2017

page(s)

47-51

1 reference

Carcinoids: the association of histologic growth pattern and survival

4 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Small cell undifferentiated carcinoma of the colon associated with hepatocellular carcinoma in an immunodeficient patient

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Thymic carcinoid. A histologic, immunohistochemical, and ultrastructural study of 12 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Treatment of neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Complete remission of refractory small cell carcinoma of the pancreas with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Prognostic variables in patients with gastrointestinal carcinoid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

An analysis of 8305 cases of carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900073-1

7 January 2021

10.1016/S1040-8428(00)00073-1

Identifiers

DOI

1 reference

4 July 2017

1 reference